Raymond James Upgrades Viking Therapeutics to Strong Buy, Raises Price Target to $116
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has upgraded Viking Therapeutics (NASDAQ:VKTX) from Outperform to Strong Buy and raised the price target from $115 to $116.

May 16, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has upgraded Viking Therapeutics from Outperform to Strong Buy and increased the price target to $116, indicating strong confidence in the company's future performance.
The upgrade from Outperform to Strong Buy and the slight increase in the price target suggest that Raymond James has a very positive outlook on Viking Therapeutics' future performance. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100